Epstein-Barr virus antibodies in Egyptian people with multiple sclerosis
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This study looks at whether people with multiple sclerosis (MS) in Egypt have higher levels of antibodies (proteins that fight infection) to the Epstein-Barr virus (EBV, a common virus that causes mono) compared to healthy people. The goal is to learn more about the possible link between EBV and MS, which might help with future understanding or treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have a confirmed diagnosis of multiple sclerosis (MS) based on the latest diagnostic criteria.
- You are not pregnant.
- You do not have HIV or viral hepatitis.
- You have no history of cancer.
- You are able to give written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether certain antiviral medicines can reduce Epstein-Barr virus (EBV) activity. If you have multiple sclerosis and evidence of EBV infection, the results may help clarify new ways to target EBV-related disease activity.
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
This early-phase study tests whether a patient’s own immune cells (made to target a common virus called EBV) are safe and practical for people who have their first episode that strongly suggests multiple sclerosis. If it works well, it could offer a new way to treat early disease—but the main goal now is safety and feasibility.
This research study looks for genetic factors that may explain why some people develop severe, long-lasting Epstein-Barr virus (EBV) infection. Researchers will study blood and tissue samples from patients with this rare condition, their healthy relatives, and unrelated volunteers to understand the disease better.
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
This trial tests a new mRNA vaccine designed to protect against the Epstein-Barr virus, which is a common virus that can cause illnesses like mono. It is for healthy young adults to see if the vaccine is safe and triggers a good immune response.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.